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TGF-(31 in glomeruloscierosis and interstitial fibrosis of adriamycin-
Induced nephropathy. The role of transforming growth factor-/3l (TGF-
/31) for renal injury was investigated in the chronic model of progressive
renal disease in rats induced by the injection of adriamycin. The renal
cortical tissues were sampled at weeks 4, 8 and 16 for histological
examination, either cortical or glomerular cell culture, and RNA
extraction. A progressive increase in fibronectin synthesis was found in
metabolically labeled cortical or glomerular culture at week 8 or 16,
correlating with the degree of glomerulosclerosis and interstitial fibro-
sis. TGF-/3 bioassay (mink lung epithelial cell assay) showed a progres-
sive increase in latent TGF-/3 secretion from cortex and glomeruli,
while the amount of active TGF-13 was small. The peak of latent TGF-/3
levels at week 16 coincided with the intense TGF-j31 staining of
inflammatory cells dispersed in the interstitium and glomeruli. Northern
blotting demonstrated the difference in the mRNA expression patterns
of TGF-/3l and latent TGF-/31 binding protein (LTBP) in the cortex.
TGF-/31 mRNA was constantly high throughout the experiment, while
LTBP mRNA increased progressively and reached a peak at week 16.
Furthermore, mRNA levels of fibronectin, procollagen a2(I), and
TGF-/3 type II and type III receptors increased progressively in a
similar pattern to the renal histological changes. These temporal and
spacial relationships between the renal histological changes and the
increased expression of TGF-131 and TGF-/3 receptors may thus suggest
that TGF-131 plays an important role in the process of the renal fibrosis
and sclerosis.
The accumulation of the extracellular matrix (ECM) [1] is a
major histological change in glomerular diseases which often
progresses to chronic renal failure [2]. The renal function
correlates well with chronic tubulointerstitial fibrosis or glomer-
ulosclerosis [3, 4]. Fibrosis or sclerosis is a complex process
requiring the participation of several cell types and ultimately
resulting in the pathological deposition of connective tissue [5].
Such deposition is probably the result of the increased synthesis
and decreased degradation of ECM which can be mediated by
the increased production of molecular signals such as cyto-
kines.
Transforming growth factor-/31 (TGF-/3l) has a potent effect
on the proliferation and differentiation of a variety of cell types
as well as a combined effect of enhancing the synthesis of ECM
[6—8], while inhibiting the proteolytic degradation of newly
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formed matrix proteins [9, 10]. In a previous study, TGF-/31
stimulated the production of ECM by cultured rat mesangial
cells [11]. In experimental glomerulonephritis, there was a close
association between the elevated expression of TGF-/31 mRNA
and the development of glomerulonephntis [12]. The treatment
of glomerulonephritis model in rats with anti-TGF-f31 antibody
prevented the histological accumulation of ECM in the glomer-
uli [13]. These results thus suggested that TGF-131 may partic-
ipate in glomerular matrix expansion. However, it is still
unknown whether TGF-/3l may play a role in the process of a
progressive renal disease.
TGF-J31 is synthesized as a TGF-/31 precursor .The C-ter-
minal of the TGF-131 precursor forms a mature TGF-/31, that is
biologically active. The N-terminal remnant of the TGF-/3l
precursor is denoted as the TGF-/31 latency associated peptide
(LAP) because it is sufficient for TGF-/31 latency. TGF-/3l is
usually secreted by normal cells in a biologically inactive or
latent form with high molecular weights [14, 15]. The latent
form of TGF-f31 is composed of three distinct components;
mature TGF-/31, LAP and latent TGF-/31 binding protein
(LTBP) [16, 17]. LAP is linked to a single molecule of LTBP by
a disulphide bond. The dissociation of LAP from mature
TGF-/31 renders TGF-f3l biologically active. Acidification,
heating and protease treatment lead to activation of latent
TGF-/3l complex in vitro, while it is still unknown how latent
TGF-/3l complex is activated in vivo.
Adriamycin(ADR)-induced nephropathy is a model of
chronic progressive focal glomerular sclerosis (FGS) in rats
[18]. The epithelial degeneration consists of an initial lesion in
the kidney, which later progresses into glomerulosclerosis and
tubulointerstitial changes [18—21]. In the present study, we
examined the role of TGF-/31 on the matrix protein synthesis
and the gene expression of LTBP and TGF-/3 receptors in the
process of glomerulosclerosis and interstitial fibrosis of ADR-
nephropathy.
Methods
Experimental design
Male Sprague-Dawley (SD) rats, weighing 220 to 250 g were
used in the present study. Experimental FGS was induced by
the intravenous injection of ADR, 0.25 mg/l00 g body weight,
dissolved in 0.9% saline, twice at 20-day intervals in SD rats
[18]. Control rats were given an intravenous injection of the
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same volume of 0.9% saline twice at the same interval. The rats
were kept in individual cages and were allowed free access to
water and regular rat chow ad libitum. The number of rats used
for each experiment is given in the figure legends. Urinary
protein was measured by the sulfosalicylic acid method at the
day before injection and at weeks 4, 8 and 16. The rats were
sacrificed at the day before the first injection (normal untreated
rats), and at 4, 8 and 16 weeks after the second injection of ADR
(the ADR rats) or only saline (the control rats). The kidneys
were perfused in situ via the aorta with phosphate-buffered
saline (PBS), pH 7.4 and then excised. The renal capsules were
removed and the cortex trimmed off with scissors. The cortex
from either the control rats or the ADR rats was saved for
preparation in either a cortical or glomerular conditioned me-
dia, glomerular RNA extraction by a sieving technique, a
histological analysis by fixing in formalin, as well as for immu-
nofluorescence and cortical RNA extraction by snap freezing in
liquid nitrogen. The cortex from the normal untreated rats was
also saved for glomerular or cortical RNA extraction.
Histological examination
The kidneys were fixed in neutral buffered formalin and
embedded in paraffin for the light microscopic study and
sections of 2-sm thickness were stained with periodic acid-
Schiff. To semiquantitate glomerular matrix, 50 glomeruli were
selected at random, and the degree of glomerular matrix expan-
sion was determined using a published method [22]. The per-
centage of each glomerulus occupied by a mesangial matrix was
estimated and assigned a score beginning with 0 0%, 1 +
to25%,2+26to50%,3+ 51to75%and4+ =76to100%.
The number of glomeruli showing a lesion of 0 was set n0, 1+
n1, 2+ n2, 3+ n3, 4+ n4, respectively. Fifty glomeruli were
examined independently, and then the sclerosis index was
obtained by the following formula :[(Oxn0+ lxn1 + 2xn2+ 3xn3+
4xn4)/50] x 100. To estimate the relative interstitial volume of
the kidney, tissue sections were examined with a 121-point (100
square) eyepiece micrometer [23]. Representative sections from
the entire cortex were analyzed by means of a point-counting
technique to obtain the relative interstitial volume. A minimum
of five sections (605 points) were randomly selected and
counted in all cases. Because the results were similar in the
control rats examined at the different times of the study, the
results for the control rats were pooled and compared with each
experimental group with Bonferroni's 1-test for independent
means. A P value of less than 0.05 was considered statistically
significant.
The method of immunohistochemical staining has been de-
scribed previously [24]. Paraffin sections were cut at 5-nm
thickness. After deparaffinization, blocking of endogenous per-
oxidase in 0.3% H202 in methanol for 30 minutes, and perme-
abilization in hyaluronidase, the sections were incubated over-
night at 4°C with anti-LC antibody (15 to 20 g/ml; provided by
Drs. K. C. Flanders and M. B Sporn, National Institutes of
Health, Maryland, USA) or ED-i (5 p,g/ml; Serotec, Oxford,
UK). Anti-LC antibody is a polyclonal antibody made against a
synthetic peptide corresponding to the first 30 amino acids of
active TGF-/31. Anti-LC antibody stains intracellular TGF-pl
[25]. ED-i is a mouse monoclonal IgG antibody which recog-
nizes cytoplasmic antigens in monocytes and macrophages [261.
After extensive washing, the sections for anti-LC antibody
were blocked with normal goat serum, then incubated with
affinity-purified goat anti-rabbit IgG and avidin-enzyme-com-
plex (Nichirei Corp., Tokyo, Japan). The sections for ED-i
were blocked with normal rabbit serum, then incubated with
affinity-purified rabbit anti-mouse IgG and avidin-enzyme-com-
plex (Nichirei Corp.). Staining was visualized by incubating
with diaminobenzidine (DAB) (Nichirei Corp.) and counter-
staining with 1% methyl green for one minute. Controls were
obtained by replacing the primary antibody with normal rabbit
IgG (Sigma Chemical Co., St. Louis, Missouri, USA) or normal
mouse IgG (Sigma) at equivalent concentration.
To examine the distribution of fibronectin and collagen type
I, the indirect immunofluorescence study was performed. Fro-
zen tissues were sectioned at 4-gm thickness using cryostat.
Air-dried sections were fixed in cold acetone, incubated with
polyclonal rabbit anti-rat fibronectin antibody (Chemicon, Te-
mecula, California, USA) or polyclonal rabbit anti-rat collagen
type I antibody (Chemicon), and then react with fluorescein-
isothiocyanate(FITC)-labeled goat anti-rabbit IgG (Organon
Teknika Corp., West Chester, Pennsylvania, USA). As control
experiments, tissue sections were incubated with normal rabbit
sera, followed by FITC-labeled goat anti-rabbit IgG, or second-
ary antibody alone.
Cortical and glomerular cell cultures
For the preparation of cortical conditioned media, pieces of
cortical tissue were weighed in a petri dish and minced with a
sharp blade into small pieces less than 1 mm in diameter, rinsed,
and suspended in serum-free RPMI-l640 (GIBCO, Grand Is-
land, New York, USA) at a concentration of 10 mg tissue per
milliliter. For the preparation of glomerular conditioned media,
the glomeruli were isolated using a graded sieving technique
[27]. A spatula was used to pass the minced cortex through a
149-pm nylon screen (Spectrum Medical, Los Angels, Califor-
nia, USA). The tissue which emerged through a nylon screen
was then passed sequentially through a 105-gm and 74-pm
sieve. Intact glomeruli retained on the 74-gm sieve were
collected, and washed three times in PBS, and resuspended at
5 x l0 glomeruli per milliliter in serum-free RPMI-1640 in
six-well multiwell plates. All glomerular preparations used
consisted of more than 95% glomeruli with minimal tubular
contamination. Mter 24 hours of incubation, these conditioned
media were harvested and centrifuged for five minutes at 4°C.
The pellet was discarded and the supernatant was collected,
aliquoted, and stored frozen at —20°C until the TGF-f3 bioassay.
The rest of the cortical and glotnerular cultures were biosyn-
thetically labeled by the addition of 200 jCi/ml of 35S-methio-
nine for 24 hours. All isotopes were obtained from American
Radiolabeled Chemicals, Inc. (St. Louis, Missouri, USA). The
culture media were harvested, phenylmethylsulfonyl fluoride,
pepstatin and aprotinin (Sigma) were added as protease inhibi-
tors, and the mixtures were centrifuged for five minutes to
remove cell debris. The samples were stored frozen at —20°C.
Electrophoretic technique
The samples for SDS-PAGE were mixed with a sample buffer
containing 3% SDS, 1 mM phenylmethylsulfonyl fluoride, and
10% 3 mercaptoethanol and heated for five minutes at 100°C
[28]. Aliquots (15 d) were equally applied to 4 to 20 gradient
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gels (Daiichi Pure Chemicals Co., Tokyo, Japan). The molecu-
lar size markers were from R&D Systems (Minneapolis, Min-
nesota, USA). Fluorography was performed by incubating gels
in Enlightning (New England Nuclear, Boston, Massachusetts,
USA). Immunoprecipitation of fibronectin was performed by
adding 100 1.d of polyclonal rabbit anti-rat fibronectin antibody
(Chemicon) to 500 d of conditioned medium as previously
described [11].
TGF-p bioassay
Mink lung epithelial cells were maintained in DMEM
(GIBCO) with 10% FCS. Subconfluent cells were used in the
TGF-13 growth inhibition assay as described by Danielpour et al
[29] with a few modifications, The cells were trypsinized,
washed with DMEM, and suspended in DMEM supplemented
with 5% FCS, 10 mmollliter HEPES, pH 7.4, penicillin (25
U/ml), and streptomycin (25 j.tglml). The cells were seeded at 2
X i0 cells per 200 d in each well of 96-well dishes. After one
hour, the conditioned media were added in dilutions of 1:10.
After 22 hours incubation the cells were pulsed with 1.0 Ci
3H-thymidine per well for two hours at 37°C. The cells were
then washed twice with 200 j.d of PBS and trypsinized and
harvested using a microculture harvesting device and counted
in liquid scintillation counter to measure 3H-thymidine incor-
poration. For each assay a standard curve was obtained with
0.03 to 3 ng/ml of a pi trifled porcine TGF-/31 (R&D Systems).
The results were expressed as the counts per minutes. To
neutralize TGF-/3 activity, a rabbit anti-TGF-13 antibody (R&D
systems) was added at a concentration of 10 ig/ml. To measure
total (latent + active) TGF-f3 activity, 1 N HC1 was added to the
conditioned media until the pH decreased to 2.0 to 2.5. After 30
minutes at room temperature, the transiently acidified media
was brought to pH 7.4 with 1 N NaOH and dialyzed against
serum-free RPMI-1640 for 24 hours at 4°C. Because the results
were similar in cortical or glomerular conditioned media from
the control rats at the different times of the study, the results for
the control rats were pooled and compared with each experi-
mental group with Bonferroni's t-test for independent means. A
P value of less than 0.05 was considered statistically significant.
RNA extraction and Northern blot analysis
Cortical tissue samples and glomeruli were isolated and
purified as described above. Total RNA was isolated from cells
using guanidine isothiocyanate, according to the method of
Chirgwin et al [30]. Ten micrograms of poiy (AY RNA from
cortex and 10 ig of total RNA from glomeruli were subjected to
electrophoresis in a 2.2 M formaldehyde-1% agarose gel, trans-
ferred to Hybond-N nylon membranes (Amersham Corp., Ar-
lington Heights, Illinois, USA), and then fixed by baking at 80°C
for two hours.
The cDNA probes used were for rat TGF-f31 and rat latent
TGF-f31 binding protein (provided by Dr. T. Nakamura, Ky-
ushu University, Fukuoka, Japan) [16], human TGF-f3 type II
receptor and rat TGF-/3 type III receptor (provided by Dr. R. A.
Weinberg, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA) [31, 32], rat fibronectin (provided by Dr.
R. 0. Hynes, Massachusetts Institute of Technology) [33],
mouse procollagen a2(I) (provided by Dr. G. Liau, J. H.
Holland Laboratory, Rockville, Maryland, USA) [34], and
Duration of ADR nephropathy, weeks
Fig. 1. The degree of glomerular sclerosis (A) and interstitial changes(B). The values are semiquantitative scores from nine rats at each point
and expressed as mean+SEM. The results for the control rats were
combined from all time points because no difference was found between
the control rats examined at the different times of the study. P < 0.01
compared with the control rats.
chicken glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
which was used as an internal control probe.
The membranes were prehybridized at least for two hours at
37°C in hybridization solution (5x SSC, 5x Denhardt's solu-
tion, 0.1 mg/mi of salmon sperm DNA, 0.1% SDS, and 50%
formamide). The cDNA probes were labeled with 32P-dCTP by
the random primer method and hybridized in the hybridization
solution at 42°C overnight. The membranes were washed twice
in 2x SSC, 0.1% SDS, and twice in lx SSC, 0.1% SDS at 42°C
for 15 minutes. Autoradiography was performed by the stan-
dard methods.
A
200
1)
0
100
0
50
40
0
30
0>
(0
20
0)
C
10
0
Control 4 8 16
Duration of ADR nephropathy, weeks
B
528 Tamaki et al: TGF-/31 in ADR nephropathy
Fig. 2. Immunofluorescence micro graphs with anti-fibronectin antibody on the renal sections from a control rat (A) and an ADR rat at week 16
(B, C); anti-rat collagen type I antibody on sections from a control rat (D) and an ADR rat at week 16 (E, F). Fibronectin and collagen type I were
present in the glomeruli and interstitium in the control rat (A, D). Increased quantities of fibronectin and collagen type I were present in the
tubulointerstitium of the ADR rat (B, F). The accumulation of both FCM proteins increased in the expanded mesangium and Bowman's capsule
of the enlarged glomerulus of the ADR rats (C, F). (A, B, D; x135, C, F, F; X270)
Results glomeruli and interstitium were fairly intact. At week 8, focal
glomerulosclerosis was scatteringly observed. Tubulointersti-
Experimental focal glomeruloscleroszs .tium showed patchy changes with flattened epithelial cells,
As described previously [181, this model of FOS showed round cell infiltration and fibrosis. At week 16, extensive
massive proteinuria immediately after ADR injection, which glomerular sclerosis and hyalinosis, tubular atrophy and inter-
continued until week 16 (date not shown). In the ADR rats at stitial fibrosis with round cell inifitration were observed. Figure 1
week 4, a light microscopic examination revealed that the shows a progressive increase in the degree of glomerular sclerosis
C 4W SW 16W
II II II I
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and interstitial fibrosis in this model. The sections from control
_____
rats showed that the glomeruli and interstitium kept mostly intact
throughout the study.
By immunofluorescence microscopy, fibronectin and colla-
gen type I were present in the glomeruli and interstitium of the
control rats. Both matrix proteins were intensely accumulated
on the scierosing glomeruli and fibrous interstitium of the ADR
rats at weeks 8 and 16 (Fig. 2).
kDa Cortical and glomerular fibronectin synthesis
÷— FN The control rats and ADR-injected rats were sacrificed for the
experiments at weeks 4, 8, and 16 after the second injection.
The cortex and glomeruli were placed in culture, and biosyn-
thetically labeled to identify any newly synthesized fibronectin,
which is the most prominent glycoprotein found in the extra-
cellular matrix. In the cortex of the ADR rats, fibronectin
synthesis was not significantly observed at week 4 as the same
as in the control. At week 8, synthesis was detected, which
reached a peak at week 16. In the glomeruli of the ADR rats,
fibronectin synthesis increased at weeks 4 and 8. At week 16,
however, the glomeruli could not be isolated from the cortex
because of the marked adhesion. Similar results were obtained
in the different experiments. Representative results are shown
in Figure 3. No difference was found in the fibronectin synthesis
between the cortical or glomerular culture from the control rats
at three different times of the study. Therefore, the results of
cortical or glomerular cultures from the control rats at week 4
are shown as a representative control in the figure.
Gene expression of fibronectin and collagen type I
kDa
200 —
116 —÷
Fig. 3. (A) Cortical fibronectin synthesis. Equal amounts of minced
cortex from either the control rats or ADR rats (N = 3 at each time
point) at weeks 4, 8 and 16, were cultured for 24 hours and biosynthet-
ically labeled with 35S-methionine. The conditioned media were immu-
noprecipitated with anti-fibronectin antibody for analysis of SDS-PAGE
with autoradiography. No difference was found in cortical fibronectin
synthesis between each of the control rats at weeks 4, 8 and 16.
Therefore, as a representative control (C), the results from the control
rats at week 4 are shown in the figure. Fibronectin synthesis of
conditioned media from ADR rats at week 4 did not significantly
increase compared to the control. At week 8, synthesis increased and
reached a peak at week 16. FN = fibronectin. (B) Glomerular fibronec-
tin synthesis. An equal number of glomeruli isolated from either the
control rats or ADR rats (N = 3 at each point) at weeks 4 and 8, were
cultured for an immunoprecipitation analysis. No difference was found
in fibronectin synthesis of glomerular conditioned media between the
control rats at weeks 4 and 8. Therefore, as a representative control (C),
the results from the control rats at week 4 are shown in the figure.
Increased fibronectin synthesis was observed in conditioned media
from ADR rats at weeks 4 and 8.
Fibronectin mRNA and procollagen a2(I) mRNA were ex-
amined in the cortex. No difference was found in mRNA
expression between each of the control rats at the different
times of the study. Fibronectin mRNA in the cortex of the ADR
rats increased progressively and reached a peak at week 16.
This result suggests that the increased fibronectin synthesis in
this model was due to an augmented transcriptional level.
Procollagen a2(I) mRNA expression in the cortex of the ADR
rats also increased progressively. Similar results were obtained
in three different experiments. Representative results are
shown in Figure 4.
Fibronectin mRNA was also examined in the glomeruli.
Glomerular RNA of the ADR rats could be extracted only from
glomeruli at week 4 but not from week 8 or 16, because the
glomerular RNA of the ADR rats at week 8 or 16 was unstable
during the isolation process. Glomerular fibronectin mRNA of
the ADR rats also increased even at week 4 compared to the
control (Fig. 5).
TGF-/3 bioassay
The conditioned media from either the cortical or glomerular
cultures were assayed for their ability to inhibit the proliferation
of mink lung epithelial cells in the control or ADR-nephropathy
rats in order to determine whether or not the diseased kidneys
were releasing increased amounts of TGF-f3. To confirm the
specificity of the assay, a rabbit polyclonal anti-TGF-/3 anti-
body, which neutralizes both TGF-J31 and -2, was used. Before
acidification, neither the cortical nor glomerular conditioned
media from the control or ADR-nephropathy had any significant
inhibitory effect on the mink lung epithelial cells compared to
A Cortex
ADR
200 —
116—*
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I I
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each medium added with anti-TGF-f3 antibody. After acidifica-
tion, cortical conditioned media from all stages, including the
control rats, showed inhibitory effects on mink lung epithelial
cell proliferation. The inhibitory effects of the acidified condi-
tioned media from the ADR rats increased progressively and
reached a peak at week 16, correlating to the degree of fibrous
changes and fibronectin synthesis in the cortex and this effect
could be reversed by anti-TGF-J3 antibody (Fig. 6A). In the
glomeruli, acidified conditioned media from the ADR rats at
weeks 4 and 8 also showed a more inhibitory effect on mink lung
epithelial cell proliferation compared to the control (Fig. 6B).
Similar results were obtained in three different experiments.
These results indicate that the TGF-/3 secreted by the cortex or
glomeruli from either the control rats or the ADR rats was
almost in a latent form while mature TGF-/3 could not be
detected in our TGF-j3 bioassay.
Gene expression of TGF-/31, LTBP, and TGF-/3 type II and
type III receptors
To verify the increase in TGF-/3 synthesis in the ADR-
nephropathy as suggested by the mink lung epithelial cell
bioassay, the amount of TGF-/31 mRNA expression was inves-
tigated in both the cortex and glomeruli. Northern blotting for
latent TGF-/31 binding protein (LTBP) mRNA in the cortex was
also investigated to determine the role of LTBP in TGF-f3
metabolism. A Northern analysis of cortical TGF-/31 mRNA for
the control rats showed a weak band as a 2.5 kb species,
suggesting that there was a low level expression of this growth
factor in the cortex. In the ADR rats, there was a marked
increase in cortical TGF-/31 mRNA at week 4, when both
fibronectin synthesis and TGF-fl secretion did not increase. The
Fig. 4. Northern blotting of fibronectin
mRNA and procollagen a2(l) mRNA in the
cortex. Ten micrograms of poiy (A) RNA
from the cortex of the normal untreated rats
(N; rats sacrificed at the day before the first
injection) or the control rats (C) and the ADR
rats (A) at 4, 8 and 16 weeks after the second
injection was loaded to each lane. Poly (A)
RNA was analyzed with rat fibronectin cDNA
or mouse procollagen a2(I) cDNA. Blots were
rehybridized with GAPDH cDNA to confirm
that approximately equal amounts of RNA
were loaded in each lane. The arrows indicate
the sizes of the major transcripts for
fibronectin (8.0 kb), procollagen a2(I) (5.7 and
4.7 kb) and GAPDH (1.3 kb).
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Fig. 5. Northern blotting of fibronectin mRNA in the glomeruli. Ten
micrograms of total RNA from the glomeruli of the normal untreated
rats (N) or the control rats (C) and the ADR rats (A) at 4 weeks after the
second injection was loaded to each lane. Glomerular RNA was
analyzed with rat fibronectin cDNA. Blots were rehybridized with
GAPDII cDNA to confirm that approximately equal amounts of RNA
were loaded in each lane. The arrows indicate the sizes of the major
transcripts for fibronectin (8.0 kb) and GAPDH (1.3 kb).
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high level of cortical TGF-/31 mRNA continued until week 16.
LTBP mRNA which was represented by two species of 5.3 and
6.2 kb, was detectable in the cortex of the control rats and the
6.2 kb species had a higher relative intensity than the 5.3 kb
species. The difference in size is attributed to the missing 5'
sequence [16]. There was no correlation in the relative mRNA
levels between LTBP and TGF-f31 in the cortex of the ADR
rats. Cortical LTBP mRNA increased progressively and
reached a maximum at week 16, and its pattern was similar to
cortical fibronectin synthesis and TGF-f3 secretion, but not to
TGF-f31 mRNA. The mRNA levels for TGF-13 type II and type
III receptors in the cortex of the ADR rats also increased
progressively and reached a maximum at week 16, which
resembled the mRNA levels for LTBP and fibronectin. The
same results were obtained in three different experiments.
Representative results are shown in Figure 7. No difference was
found in mRNA expression between each of the control rats at
the different times of the study.
Glomerular RNA could be extracted only from the ADR rats
at week 4 but not from week 8 or 16, because the glomerular
RNA of the ADR rats at week 8 or 16 was unstable during the
isolation process. Glomerular TGF-J3l mRNA of the ADR rats
also increased even at week 4 compared to the control (Fig. 8).
Cells synthesizing TGF-131
Anti-LC is an antibody made against a synthetic peptide from
TGF-f3l that reacts with cells that are thought to be synthesiz-
ing TGF-f31. We used anti-LC antibody to detect TGF-f3l
producing cells in the cortical tissue. Anti-LC positive cells
were not observed in the control rats, while intracellular
staining with anti-LC antibody was detected in the tubular
epithelial cells and a small number of infiltrating cells in the
interstitium of the ADR rats at week 8. An increasing number of
infiltrating cells which were stained with the anti-LC antibody
were seen associated with the area of increased cellularity in the
interstitium and glomeruli of the ADR rats at week 16 (Fig. 9).
To identify the type of infiltrating cells in the interstitium,
cortical tissues were also stained with ED-l, which is a mouse
monoclonal IgG antibody to monocytes and macrophages.
ED-I positive cells were not detected in the glomeruli or the
interstitium of the control rats. A number of ED-l positive
macrophages were observed in both the glomeruli and the
interstitium of the ADR rats at weeks 8 or 16 (Fig. 9). Although
the distribution and the morphological appearance of anti-LC
positive cells in the interstitium were similar to those of the
ED-i positive macrophages, the number of anti-LC positive
cells was smaller than that of the ED-i positive macrophages.
Discussion
The histological and physiological studies on adriamycin-
induced nephropathy have been extensively done and reported
from our laboratory [18—21]. This nephropathy is a reproducible
model of glomeruloscierosis and chronic interstitial fibrosis
associated with nephrotic syndrome. Histological changes in
the kidney include the marked accumulation of extracellular
matrix (ECM) in relation to the increase of the parenchymal
cells, which is an important feature of this model to end-stage
renal destruction. Extensive fibronectin and collagen type I
deposition was revealed in the sclerosing glomeruli and fibrous
interstitium in this model. Both matrix proteins are key molec-
Fig. 6. (A) TGF-13 activity in cortical conditioned media from either the
control rats or ADR rats at weeks 4, 8 and 16, assayed before (0) or
after acidification (a). Each sample was assayed in either the presence
or absence of anti-TGF-/3 antibody. Each value represents the mean of
6 samples from 3 rats. Before acidification, the conditioned media had
no significant inhibitory effects on mink lung epithelial cells. After
acidification, conditioned media showed inhibitory effects on the cell
proliferation. The inhibitory effects of acidified conditioned media from
the ADR rats increased progressively and reached a peak at week 16.
This inhibition was reversed by addition of anti-TGF-p antibody. The
results for the control rats have been combined from all time points
because no difference was found between the control rats examined at
the different times of the study. Values are mean+5EM. *D < 0.005
compared to the control. (B) TGF-/3 activity in glomerular conditioned
media from the control rats or ADR rats at weeks 4 and 8. The acidified
conditioned media at weeks 4 and 8 showed more inhibitory effects on
mink lung cell epithelial cell proliferation compared to the control. The
results for the control rats have been combined from all time points
because no difference was found between the control rats examined at
the different times of the study. *P < 0.05 compared to the control.
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ular components found in ECMs of interstitium. Fibronectin
first appears prior to other matrix proteins in scarring tissues
[35] and provides a scaffold for the deposition and fibrogenesis
of interstitial collagens [36]. The present study also demon-
strated that nn increased fibronectin synthesis in glomerular or
cortical culture was correlated with the glomerulosclerosis or
interstitial fibrosis in this model.
Although many cytokines may be implicated in sclerotic and
fibrotic responses consequent to adriamycin-induced renal in-
jury, TGF-13l seems to be a main factor in regulating sclerosis
and fibrosis because of its widespread effects on ECMs.
TGF-/31 actions on ECMs are mediated through regulatory
effects on: (a) ECM synthesis [6—8J, (b) enzymes that degrade
ECM [9, 10], and (c) the expression of ECM receptor on cells
[37]. In fact, TGF-/31 has a dramatic effect on the production of
ECM in the cultured rat glomerular mesangial cells [11]. An
Fig. 7. Northern blotting of TGF-f31 ,nRNA,
LTBP mRNA and TGF-13 type II and type HI
receptors mRNA in the cortex. Ten
micrograms of poly (A)RNA from the cortex
of the normal untreated rats (N; rats sacrificed
at the day before the first injection) or the
control rats (C) and the ADR rats (A) at 4, 8,
16 weeks after the second injection was
loaded to each lane. Poly(A)RNA was
analyzed with the EcoRl/BglI fragment of rat
TOE-fl cDNA. LTBP mRNAs were detected
by the cDNA insert of LTBP clone RMS.
Hybridization with human TOE-fl type II
receptor cDNA and rat TOE-fl type III
receptor eDNA was also performed. Finally
blots were rehybridized with OAPDH eDNA
to confirm that approximately equal amounts
of RNA were loaded in each lane. The arrows
indicate the sizes of the major transcripts for
TOE-fl (2.5 kb), LTBP (6.2 and 5.3 kb),
TOE-fl type II receptor (5.5 kb), TOE-fl type
III receptor (6.0 kb) and OAPDH (1,3 kb).
experimental model of glomerulonephritis, anti-Thy-i nephritis
in the rats, was associated with the increased production and
activity of TOF-fli [12]. The suppression of the experimental
disease achieved with anti-TGF-/3i antibody treatment indi-
cates the importance of TOF-pi in regulating ECM production
in glomerulonephritis [13].
In the present study of adriamycin-induced nephropathy, the
progressive increase in TGF-/3 synthesis obtained by a bioassay
using mink lung epithelial cells resembled the pattern of cortical
or glomerular fibronectin production. It is noteworthy that
the elevation of TGF-fii mRNA preceded the increase in the
fibronectin synthesis and mRNA. Immunohistologically,
TOP-flu was identified in tubular epithelial cells and infiltrating
cells in the interstitium at week 16, which coincided with the
peak TOF-fl secretion by kidney tissues. These results suggest
that the increased expression of TOF-/31 may be related to the
TGF- type II
receptor 4— 5.5
GAPHD 4-1.3
iii
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latency associated peptide (LAP) and latent TGF-/3l binding
protein (LTBP). LAP is necessary for TGF-/31 latency and the
dissociation of LAP from mature TGF-/31 renders TGF-/3l
biologically active. Although acidification, heating and protease
treatment have been shown to be effective for TGF-f31 activa-
tion in vitro, it is still unknown how this latent TGF-/3l complex
is activated in vivo.
In the acute glomerulonephntis models, however, mature
TGF-/31 was detected in either cortical or glomerular cultures
[12, 41]. A protease or specific activation factor that is produced
at active inflammatory sites may lead to the release of mature
TGF-/3l from the latent complex through a limited proteolysis
of LAP. In contrast, a small amount of mature TGF-/31 in the
conditioned media from ADR-nephropathy rats indicates that
only a slight amount of proteases activating the latent TGF-/31
complex were secreted from the tissue, which may be related to
the chronicity of this model.
In this model, persistent ECM synthesis may be chronically
stimulated by a small amount of mature TGF-13l, being acti-
vated by another mechanism. Some studies using a co-culture
technique suggest that direct interaction of the latent TGF-/3l
complex and a cell-surface molecule is necessary for the
activation of the latent complex [42]. It is also demonstrated
that LTBP participates in the activation of the latent TGF-/3l
complex probably due to concentrating the latent growth factor
on the cell surface where activation occurs [43]. Epidermal
growth factor(EGF)-like domains and the internal repeats with
eight cysteins in LTBP may act as a functional domain to
release mature TGF-/31 from the latent complex by the interac-
tion with a cell surface or matrix macromolecule [16, 43]. Our
present study indicates the possibility that LTBP, of which
mRNA increased progressively with a similar pattern to latent
TGF-/3 secretion and fibronectin synthesis, may play an impor-
tant role in the activation of latent TGF-/31 complex in this
model of renal fibrosis.
The latent TGF-f3 secretion by the cortex was preceded by an
increase in TGF-131 mRNA at week 4. The discrepancy between
the kinetics of TGF-p synthesis and the increased message
expression is unknown at present but may be explained by the
discrepancy between TGF-f31 mRNA and LTBP mRNA. In rat
tissues, there is usually a good correlation between LTBP
mRNA and TGF-/31 mRNA in various tissues except for the
thymus [16]. This suggests that LTBP mRNA is synthesized in
parallel with the expression of TGF-f31 mRNA in a normal
tissue. The present study is the first report that demonstrated a
discrepancy between LTBP mRNA and TGF-f31 mRNA in
diseased tissue. In this model, the latent TGF-3 secretion
coincided to LTBP mRNA rather than TGF-/31 mRNA. This
finding indicates that LTBP may have an ability to regulate
latent TGF-f3 secretion in the diseased kidney. There is also a
recent report that LTBP plays a critical role in the assembly and
secretion of latent TGF-f31 complex [44]. The TGF-j31 precur-
sor remains inside the cells in an unprocessed form for a longer
time period and the TGF-/31 precursor dimer without LTBP is
secreted very slowly. In contrast, the latent TGF-/31 complex is
secreted rapidly after the synthesis of LTBP.
Another possible explanation for the discrepancy of TGF-/31
mRNA and LTBP mRNA may be partly due to the cell
component. The intrinsic cell proliferation (for example, me-
sangial cell) or cell infiltration (for example, macrophage or
4W
I I
kb
TGF-31
GAPDH
Fig. 8. Northern blotting of TGF-/31 mRNA in the glomeruli. Ten
micrograms of total RNA from the glomeruli of the normal untreated
rats (N) or the control rats (C) and the ADR rats (A) at 4 weeks after the
second injection were loaded to each lane. Glomerular RNA was
analyzed with the EcoRI/BglI fragment of rat TGF-/31 eDNA. Blots
were rehybridized with GAPDH cDNA to confirm that approximately
equal amounts of RNA were loaded in each lane. The arrows indicate
the sizes of the major transcripts for TGF-/31 (2.5 kb) and GAPDH
(1.3 kb).
process of glomerulosclerosis and interstitial fibrosis in ADR-
nephropathy.
A part of tubular epithelial cells and infiltrating cells was
stained with anti-LC antibody, which is considered to react
with TGF-/31 producing cells. Previous reports using this anti-
body indicate that macrophages and alveolar epithelial cells are
TGF-f31 producing cells in pulmonary fibrosis [38] and macro-
phages in renal fibrosis [39]. In the present study, the number of
cells which were stained with anti-LC antibody was smaller
than we expected, if, in fact, the main TGF-/31 producing cells
are macrophages. Indeed, the number of ED-l positive macro-
phages was larger than that of anti-LC positive cells in our
study. These findings suggest that not all macrophages infiltrat-
ing into the mterstitium and glomeruli secrete TGF-/31 but only
a part of the macrophages, probably the activated macrophages
[40] found in the damaged tissue and tubular epithelial cells are
a likely source of TGF-f3l.
Acidification of the conditioned media from cortex or glomer-
uli caused a progressive increase in total TGF-f3 activity which
correlated well with the degree of histological changes, while
the non-acidified media failed to show any significant TGF-13
activity. These findings suggest that most of the TGF-f31 is
present in a latent form throughout the entire process of the
disease. TGF-f31 is known to be synthesized and secreted in a
latent form from a wide variety of cells [14, 15]. As described
above, latent TGF-f31 complex is composed of mature TGF-/31,
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Fig. 9. Immunohistochemical localization of anti-TGF-/31 (anti-LC) antibody on renal sections from a control rat (A) and an ADR rat at week 16(B, C, D, E); ED-I on sections from a control rat (F) and an ADR rat at week 16 (G, H). An avidin-biotin-DAB detection system was used with
methyl green counter stain. Anti-LC antibody positive cells were not detected in the cortical tissue sections in the control rat (A). Anti-LC antibody
localized in the cytoplasma of infiltrating cells adjacent to the area of hypercellularity (B), in interstitial infiltrating cells in cluster (C), in tubular
epithelial cells (D), and in a glomerular cell (E) in the ADR rat (arrows). No ED-i positive cells were observed in the control rat (F). A number
of ED-i positive macrophages were detected in the interstitium (G) and glomeruli (H) in the ADR rat. (x280)
fibroblast) may contribute to expression of messenger RNA. A
recent study using an immunohistochemical examination in
carcinoma and granulation tissue in the human gastrointestinal
tract, indicates that fibroblasts produce both TGF-/31 precursor
and LTBP, and that cancer cells and macrophages produce only
TGF-/31 precursor [45]. Further studies using immunohisto-
chemistry or in situ hybridization will be needed to better
identify the type of cells expressing TGF-/31 precursor or LTBP
in ADR-induced nephropathy.
In the present study, we also examined mRNA levels for
TGF-/3 type II and type III receptors, which increased progres-
sively with a similar pattern to fibronectin mRNA and LTBP
mRNA. TGF-131 bind to at least three different receptors type I,
II and III. Type I and type II receptors are most important for
the signal transduction whereas the function of type III receptor
is thought to act as a reservoir or capacitor of TGF-/31 and to
regulate either the ligand-binding ability or surface expression
of the type II receptor [32, 46]. TGF-f3 type II receptor has been
recently cloned and has a cytoplasmic serine/threonine kinase
domain which is not yet fully understood [311. Our results may
thus indicate the possibility that the TGF-/31 and TGF-f3 recep-
tors are progressively augmented in the diseased tissue and are
therefore involved in fibrosis in this model.
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